GlassScriptPhysician profile
Christine Schaffer
NPI 1407866866
$256.69
in general payments reported to CMS, 2019-2025
8 companies · $17.92 in 2025
The $17.92 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.09 · 2020: $17.09 · 2021: $38.21 · 2022: $31.15 · 2023: $81.75 · 2024: $32.48 · 2025: $17.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.12 | 2021-2025 | Camzyos |
| Pfizer INC. | $37.35 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $36.58 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.12 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $25.23 | 2019-2022 | |
| Inari Medical, INC. | $25.06 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Otsuka America Pharmaceutical, INC. | $14.84 | 2019 | |
| Celgene Corporation | $13.39 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.